PUT/ROCHE GS/300/0.1/21.06.24 Share Price

Warrant

DE000GP4PZR5

Real-time BOERSE MUENCHEN 15:27:28 07/06/2024 BST
5.89 EUR -8.11% Intraday chart for PUT/ROCHE GS/300/0.1/21.06.24
Current month-10.35%
1 month-23.05%
Date Price Change
07/06/24 5.89 -8.11%
06/06/24 6.41 -2.73%
05/06/24 6.59 -3.37%
04/06/24 6.82 -3.67%
03/06/24 7.08 -0.98%

Real-time BOERSE MUENCHEN

Last update June 07, 2024 at 03:27 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellPUT
Underlying ROCHE HOLDING AG
Issuer Goldman Sachs
WKN GP4PZR
ISINDE000GP4PZR5
Date issued 11/05/2023
Strike 300 CHF
Maturity 21/06/2024 (14 Days)
Parity 10 : 1
Emission price 3.39
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 8.82
Lowest since issue 2.69
Spread 0.05
Spread %0.84%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
238.1 CHF
Average target price
277.5 CHF
Spread / Average Target
+16.56%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW